Episode 2: Navigating common treatment scenarios in HER2-mutant NSCLC This is the second episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology Brothers, Drs Rohit and Rahul Gosain. In this episode Drs Isabel Preeshagul and Eric Singhi provide the benefit of their experience when discussing how to approach different treatment scenarios in HER2-mutant NSCLC. The conversation unfolds to cover; How to distinguish HER2 alterations from other alterations on biomarker reports The latest efficacy and safety data of currently approved and emerging treatments for HER2-altered NSCLC The potential CNS activity of these treatments in patients with HER2-mutated NSCLC How the treatment pathway may look in the near future You can also watch a video of the experts in conversation and download the transcript on our website: https://cor2ed.com/lung-connect/programmes/her2-diagnostic-treatment-nsclc-2/ Or watch on YouTube: https://youtu.be/E8-3GDyJT9Y Follow LUNG CONNECT on social media: X – https://x.com/lung_connect LinkedIn – https://www.linkedin.com/company/lungconnect/ This content is intended for healthcare professionals only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Bayer. This podcast is developed by cor2ed.com Published on May 2025 Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related